Gastrointestinal perforation in metastatic carcinoma: A complication of bevacizumab therapy

European Journal of Surgical Oncology

Volumn 35, Issue 4, 2009, Pages 444-446

  Collins, D ^a   Ridgway, P F ^a   Winter, D C ^a   Fennelly, D ^a   Evoy, D ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Bevacizumab; Colorectal carcinoma; Gastrointestinal perforation

Indexed keywords

BEVACIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ACUTE ABDOMEN; ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; EMERGENCY SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PERITONITIS; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; SURGICAL MORTALITY; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ABDOMINAL PAIN; AGED; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CARCINOMA; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; INTESTINAL PERFORATION; MALE; MIDDLE AGED; WOUND HEALING;

EID: 60849127884     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.02.013     Document Type: Article

References (14)

1. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
2. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
3. Saif M.W., Elfiky A., and Salem R.R. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14 (2007) 1860-1869
4. Setti Carraro P.G., Segala M., Orlotti C., and Tiberio G. Outcome of large bowel perforations in patients with colorectal cancer. Dis Colon Rectum 41 (1998) 1421-1426
5. Mandava N., Kumar S., Pizzi W.F., and Aprile J. Perforated colorectal carcinomas. Am J Surg 172 (1996) 236-238
6. McArdle C.S., and Hole D.J. Emergency presentation of colorectal cancer is associated with poor 5 year survival. Br J Surg 91 (2004) 605-609
7. Khan S., Pawlak S.E., Eggenberger J.C., Lee C.S., Szilagy E.J., and Margolin D.A. Acute colonic perforation associated with colorectal cancer. Am Surg 67 (2001) 261-264
8. Badgwell B., Feig B.W., Ross M.I., Mansfield P.F., Wen S., and Chang G.J. Pneumoperitoneum in the cancer patient. Ann Surg Oncol 14 (2007) 3141-3147
9. Heinzerling J.H., and Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63 (2006) 334-337
10. Kretzschmar A, Cunningham D, Berry S, et al. Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumour resection: preliminary results from the first BEATrial (abstract 248). Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium; 2006.
11. Sugrue M., Kozloff M., Hainsworth J., et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. ASCO Meeting Abstracts. J Clin Oncol 20 (June 2006) 3535
12. Morris C.R., Harvey I.M., Stebbings W.S., Speakman C.T., Kennedy H.J., and Hart A.R. Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease. Br J Surg 90 (2003) 1267-1272
13. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 1 (2005) 173-180
14. Pavlidis T.E., Galatianos I.N., Papaziogas B.T., et al. Complete dehiscence of the abdominal wound and incriminating factors. Eur J Surg 167 (2001) 351-354